Definium Therapeutics, Inc.
DFTX
$42.63
-$1.27-2.89%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 48.92% | 26.17% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 26.78% | 24.47% | |||
| Operating Income | -26.78% | -24.47% | |||
| Income Before Tax | -106.21% | -52.86% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -106.21% | -52.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -106.21% | -52.86% | |||
| EBIT | -26.78% | -24.47% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -102.68% | -41.91% | |||
| Normalized Basic EPS | -102.69% | -41.91% | |||
| EPS Diluted | -102.82% | -41.97% | |||
| Normalized Diluted EPS | -102.69% | -41.91% | |||
| Average Basic Shares Outstanding | 1.74% | 7.71% | |||
| Average Diluted Shares Outstanding | 1.74% | 7.71% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||